Prostate cancer screening

Pathology

Volumn 44, Issue 2, 2012, Pages 99-109

  Sikaris, Ken ^a  

^a MELBOURNE PATHOLOGY   (Australia)

Author keywords

Age related PSA reference limits; Free to total PSA ratio; Median PSA; Prostate cancer; Prostate specific antigen; PSA doubling time; Screening

Indexed keywords

EID: 84858311564     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834fbb2c     Document Type: Article

References (177)

1. Delongchamps NB, Singh A, Haas GP. Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer 2007; 31: 226-36. (Pubitemid 46818421)
2. The Cancer Council South Australia. Statistics: prostate cancer. March 2008 (cited November 2011). http://www.cancersa.org.au/cms-resources/ PROSTATE%20STATISTICS%20for%202005.pdf
3. Mortality from cancer. In: Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries. Cancer in Australia: An Overview, 2010. Canberra: AIHW, 2010; 22-3. Cancer series no. 60. Cat. no. CAN 56.
4. Burden of disease due to cancer. In: Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries. Cancer in Australia: An Overview, 2010. Canberra: AIHW, 2010; 60-3. Cancer series no. 60. Cat. no. CAN 56.
5. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008; 15: 3866-71.
6. Hsing AW, Devesa SS, Jin F, Gao YT. Rising incidence of prostate cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev 1998; 7: 83-4. (Pubitemid 28087146)
7. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60-7.
8. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute. 2011 (cited November 2011). http://seer.cancer.gov/csr/1975-2008/.
9. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age at diagnosis and age at death in familial prostate cancer. Oncologist 2009; 14: 1209-17.
10. Paquette EL, Sun L, Paquette LR, Connelly R, Mcleod DG, Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60: 756-9. (Pubitemid 35300331)
11. Huggins CB. The hormone dependent cancers. Bull N Y Acad Med 1963; 39: 752-7.
12. Young HH. Early diagnosis and radical cure of carcinoma of the prostate. Bull Johns Hopkins Hosp 1905; 16: 314-21.
13. Dennis PM, Stringer MA, Sikaris KA. Causes for concern with the use of PSA assays. Med J Aust 1994; 161: 230.
14. Richie JP, Kavoussi LR, Ho GT, et al. Prostate cancer screening: role of the digital rectal examination and prostate-specific antigen. Ann Surg Oncol 1994; 1: 117-20.
15. Reis LO, Zani EL, Alonso JC, Simões FA, Rejowski RF, Ferreira y U. Impacta el criterio para indicar la biopsia prostática sobre su exactitude. Estudio prospectivo llevado a cabo sobre una población de pacientes ambulantes. Actas Urológicas Españolas 2011; 35: 10-4.
16. Thompson IM, Ernst JJ, Gangai MP, Spence CR. Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984; 132: 690-2. (Pubitemid 14017005)
17. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1C) prostate cancer. JAMA 1994; 271: 368-74. (Pubitemid 24037911)
18. Schroder FH, Vandermas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998; 90: 1817-23. (Pubitemid 28559894)
19. Roobol MJ, van Vugt HA, Loeb S, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2011; Nov 15:. Epub ahead of print
20. Sequoia JSP, Wright ME, McCarron P, et al. A prospective investigation of height and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 2174-8. (Pubitemid 44877043)
21. Banez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemo-dilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-80. (Pubitemid 350146217)
22. Beebe-Dimmer JL, Faerber GJ, Morgenstern H, et al. Body composition and serum prostate specific antigen: a review and findings from the Flint Men's Health Study. Urology 2008; 71: 554-60.
23. Gutman AB, Gutman EB. An acid phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938; 17: 473-8.
24. Bogdanowicz JF, Bentvelsen FM, Oosterom R, Schroeder FH. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1991; 138: 97-103.
25. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980; 40: 2428-32. (Pubitemid 10082262)
26. Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40: 4658-62. (Pubitemid 11199734)
27. Purnell DM, Heatfield BM, Trump BF. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen. Cancer Res 1984; 44: 285-92. (Pubitemid 14177752)
28. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16. (Pubitemid 17147932)
29. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
30. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-90. (Pubitemid 34814727)
31. Colberg JW, Smith DS, Catalona WJ. Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng/ml. J Urol 1993; 149: 507-9. (Pubitemid 23094040)
32. Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol 1994; 25: 281-7. (Pubitemid 24155560)
33. Sassine AM, Schulman C. Value of PSA in the staging of prostatic cancer. Acta Urol Belg 1992; 60: 49-59.
34. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71: 589-93. (Pubitemid 23021255)
35. Shröder FH, Damhuis RA, Kirkels WJ, et al. European randomized study of screening for prostate cancerthe Rotterdam pilot studies. Int J Cancer 1996; 65: 145-51. (Pubitemid 26048912)
36. Raaijmakers R, de Vries SH, Blijenberg BG, et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10ng/ml. Eur Urol 2007; 52: 1358-64. (Pubitemid 47445980)
37. Blijenberg BG, Roobol M, Schröder FH. Analytical issues on prostate-specific antigen in relation to prostate cancer screening. Clin Biochem 1998; 31: 633-9. (Pubitemid 29021473)
38. Fillée C, Tombal B, Philippe M. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays. Clin Chem Lab Med 2010; 48: 285-8.
39. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543.
40. Barry MJ. Screening for prostate cancerthe controversy that refuses to die. N Engl J Med 2009; 360: 1351-4.
41. Andriole GL, Crawford ED, Grubb RL, 3rd et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 26: 1310-9.
42. Prorok PC, Andriole GL, Bresalier RS, et al. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21 (Suppl 6): 273S-309S.
43. Vickers AJ, Lilja H. Cutpoints in clinical chemistry: time for fundamental reassessment. Clin Chem 2009; 55: 15-7.
44. Kolata G. It was medical gospel, but it wasn't true. New York Times 2004; May 30: 4,7.
45. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical BiochemistryNational Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54: e11-79. (Pubitemid 352777353)
46. Crawford ED, Grubb R III, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011; 29: 355-61.
47. Nieder C, Dalhaug A, Pawinski A, Aandahl G, Norum J. Comorbidity, use of common medications, and risk of early death in patients with localized or locally advanced prostate cancer. Scientific World Journal 2011; 11: 1178-86.
48. Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, Venn S. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis 2006; 9: 270-4. (Pubitemid 44317262)
49. van Leeuwen PJ, Connolly D, Gavin A, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 2010; 46: 377-83.
50. Roobol MJ, Kerkhof M, Schroder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for non-attendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSCP). Eur Urology 2009; 56: 584-91.
51. Roobol MJ, Kerkhof M, Schröder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for non-attendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584-91.
52. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2011; 29: 464-7.
53. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32.
54. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. US Preventive Services Task ForceScreening for breast cancer: An update for the US Preventative Services Task force. Ann Int Med 2009; 151: 727-37.
55. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, haemoccult. Br Med J 1998; 317: 559-65. (Pubitemid 28395924)
56. Draisma G, Etzioni R, Tsodikov A, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78. (Pubitemid 36833878)
57. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011; 342: 1539-44.
58. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11 year follow up of the Quebec prospective randomised control trial. Prostate 2004; 59: 311-8. (Pubitemid 38509764)
59. Ilic D, O'Connor D, Green S, Wilt T. Screening for Prostate cancer. Cochrane Database Syst Rev 2006; 3: CD004720.
60. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J Urol 2009; 181: 1615-21.
61. Lumen N, Fonteyne V, De Meerleert G, et al. Population screening for prostate cancer: An overview of available studies and meta-analysis. Int J Urol 2011; Nov 22:. Epub ahead of print.
62. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 18: 860-4. (Pubitemid 23234116)
63. Rochester MA, Donaldson PJ, McLoughlin J. Perception of abnormal serum prostate-specific antigen (PSA) test results amongst family practitioners. Ann R Coll Surg Engl 2008; 90: 398-402.
64. Melia J, Coulson P, Coleman D, Moss S. Urological referral of asymptomatic men ingeneral practice in England. BrJ Cancer 2008; 98: 1176-81. (Pubitemid 351481676)
65. Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol 2008; 129: 952-8.
66. Kort SAR, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006; 52: 1568-74. (Pubitemid 44148320)
67. Chen Z, Prestiglacomo A, Stamey TA. Purification and characterization of prostate-specific antigen (PSA) complexed to a1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin Chem 1995; 41: 1273-82.
68. Jansen FH, Roobol M, Bangma CH, van Schaik RHN. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem 2008; 54: 1999-2006. (Pubitemid 352774033)
69. Stephan C, Kahrs AM, Klotzek S, et al. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med 2008; 46: 623-9 (Pubitemid 351749111)
70. Stephan C, Siemen K, Cammann H, et al. Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. Clin Chem 2011; 57: 995-1004.
71. Cheng I, Yu MC, Koh WP, et al. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States. Cancer Epidemiol Biomarkers Prev 2005; 14: 1692-6. (Pubitemid 40995081)
72. Grunkemeier MN, Vollmer RT. Predicting prostate biopsy results: the importance of PSA, age, and race. Am J Clin Pathol 2006; 126: 110-2. (Pubitemid 44025078)
73. Carter HB, Kettermann AE, Ferrucci L, Landis P, Trock BJ, Metter EJ. Prostate specific antigen testing among the elderly; when to stop. J Urol 2008; 174 (Suppl 1): 600; (Abstr 1751).
74. Kubota Y, Sasagawa I, Sinzawa H, et al. Serum levels of free and total prostate-specific antigen in males with liver cirrhosis. Eur Urol 1999; 36: 409-12. (Pubitemid 29452711)
75. Birkenmeier G, Struck F, Gebhardt R. Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin. J Urol 1999; 162: 897-901. (Pubitemid 29436913)
76. Richardson TD, Wojno KJ, Liang LW, et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology 1996; 48: 40-4. (Pubitemid 26425534)
77. Brändle E, Hautmann O, Bachem M, et al. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomya critical assessment. Urology 1999; 53: 722-30. (Pubitemid 29163036)
78. Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A. Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1238-41.
79. Ku JH, Kim ME, Lee NK, Park YH, Ahn JO. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 2003; 61: 132-6. (Pubitemid 36151728)
80. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7. (Pubitemid 28233009)
81. Hoffman RM, Clanon DL, Littenberg B, Frank JJ, Pierce JC. Using free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med 2000; 15: 739-48.
82. Karakiewicz PI, Benayoun S, Kattan MW, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005; 173: 1930-4. (Pubitemid 40675214)
83. Aus G, Becker C, Franze S, Lilja H, Lodding P, Hugosson J. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol 2004; 45: 160-5. (Pubitemid 38147821)
84. Walz J, Haese A, Scattoni V, et al. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer 2008; 113: 2695-703.
85. Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G. Prostate carcinoma screening in the county of Tyrol, Austria; experience and results. Cancer 1997; 80: 1818-29. (Pubitemid 27475944)
86. Lee BH, Moussa AS, Li J, Fareed K, Jones JS. Percentage of free prostate-specific antigen: implications in modern extended scheme prostate biopsy. Urology 2011; 77: 899-903.
87. Sikaris KA. Letter: It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials. Med J Aust 2010; 193: 61.
88. Allard C, Yip P, Blasutig I, Hersey K, Fleshner N. Does the reflexive measurement of free PSA have a role in a tertiary cancer centre? Can Urol Assoc J 2010; 4: 317-20.
89. Arneth BM. Error in the calculation of the PSA quotient. Clin Biochem 2009; 42: 722-4.
90. McIntosh MW, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Bio-markers Prev 2002; 11: 159-66. (Pubitemid 34202997)
91. McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 2003; 4: 27-40. (Pubitemid 36116886)
92. Bruun L, Becker C, Hugosson J, Lilja H, Christensson A. Assessment of intra-individual variationin prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 2005; 65: 216-21. (Pubitemid 41443726)
93. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem 2002; 35: 471-5. (Pubitemid 35284544)
94. Soletormos G, Semjonow A, Sibley PEC, et al. on behalf of the European Group on Tumor MarkersBiological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005; 51: 1342-51. (Pubitemid 41060864)
95. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-7. (Pubitemid 44680903)
96. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007; 70: 685-90. (Pubitemid 350030209)
97. Moul JW, Sun L, Hotaling JM, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007; 177: 499-503.
98. Delahunt B, Srigley JR, Lamb DS. Gleason grading: consensus and controversy. Pathology 2009; 41: 613-4.
99. Delahunt B, Lamb DS, Srigley JR, et al. Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point. Pathology 2010; 42: 339-43.
100. Pinsky PF, Andriole G, Crawford ED, et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007; 109: 1689-95. (Pubitemid 46595706)
101. Nowroozi MR, Zeighami S, Ayati M, et al. Prostate-specific antigen doubling time as a predictor of gleason grade in prostate cancer. Urol J 2009; 6: 27-30.
102. Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schroder FH, van der Kwast TH. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 2005; 103: 708-16. (Pubitemid 40216398)
103. Vollmer RT, EgawaS, KuwaoS, Baba S. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma. Cancer 2002; 94: 1692-8. (Pubitemid 34241106)
104. Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology 1997; 49: 737-42. (Pubitemid 27194590)
105. Schmid HP. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times. Cancer Surv 1995; 23: 157-67.
106. Loeba S, Kettermanna A, Ferrucci L, Landisa P, Metter EJ, Carter HB. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008; 54: 1073-80.
107. O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27: 3591-7.
108. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403.
109. Nanda A, Chen MH, D'Amico AV. Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority. J Clin Oncol 2009; 27: 1728-9.
110. Egawa S, Arai Y, Tobisu K, et al. Use of pretreatment prostatespecific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000; 3: 269-74. (Pubitemid 32066537)
111. Arlen PM, Bianco F, Dahut WL, et al. Prostate-Specific Antigen Working Group's Guidelines on PSA Doubling Time. J Urol 2008; 179: 2181-6.
112. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006; 106: 1047-53.
113. Benecchi L, Pieri AM, Pastizzaro CD, Potenzoni M. Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis. J Urol 2011; 185: 821-6.
114. Vollmer RT. Dissecting the dynamics of serum prostate-specific antigen. Am J Clin Pathol 2010; 133: 187-93.
115. Bellera CA, Hanley JA, Joseph L, Albertsen PC. Detecting trends in noisy data series: application to biomarker series. Am J Epidemiol 2008; 167: 1130-9. (Pubitemid 351601237)
116. Shimbo M, Tomioka S, Sasaki M, et al. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer. Jpn J Clin Oncol 2009; 39: 727-31.
117. Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc 2007; 82: 422-7. (Pubitemid 46543465)
118. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem 2005; 41: 430-4.
119. Doherty AP, Bower M, Smith GL, et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000; 83: 1432-6
120. Erbudak M, Erzan A. Tracking tumor evolution via prostate-specific antigen: an individual post-operative study. Theor Biol Med Model 2010; 7: 30-7.
121. Leite KR, Srougi M, Dall'Oglio MF, Sanudo A, Camara-Lopes LH. Histopathological findings in extended prostate biopsy with PSA <4ng/mL. Int Braz J Urol 2008; 34: 283-92.
122. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005; 97: 1132-7. (Pubitemid 41511212)
123. Walz J, Haese A, Scattoni V, et al. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5ng/mL and lower. Cancer 2008; 113: 2695-703.
124. Ishidoya S, Ito A, Orikasa K, et al. The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%. Jpn J Clin Oncol 2008; 38: 844-8.
125. Yamamoto S, Maruyama T, Kondoh N, et al. Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml. Int Urol Nephrol 2008; 40: 85-9. (Pubitemid 351459875)
126. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004; 171: 2239-44. (Pubitemid 38625443)
127. Le BV, Griffin CR, Loeb S, et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 1355-9.
128. Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 2011; 21: 225-9.
129. Auprich M, Bjartell A, Chun FK, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011; 60: 1045-54.
130. Johansson M, Holmström B, Hinchliffe SR, et al. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study. Int J Cancer 2012; 130: 129-37.
131. Lutz AM, Willmann JK, Cochran FV, Ray P, Gambhir SS. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Medicine 2008; 5: 1287-97.
132. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/mL or lower. JAMA 2005; 294: 66-70. (Pubitemid 41002840)
133. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <4.0ng per milliliter. N Engl J Med 2004; 350: 2239-46.
134. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34. (Pubitemid 43898816)
135. Vickers AJ, Cronin AM, Björk T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010; 14: 341.
136. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006; 67: 316-20. (Pubitemid 43189848)
137. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict longterm risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58: 411-6. (Pubitemid 32816360)
138. UlmertD, Cronin AM, Björk T, etal. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008; 6: 6.
139. Tang P, Sun L, Uhlman MA, et al. Initial prostate specific antigen 1.5ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol 2010; 183: 946-51.
140. Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH. Baseline prostate-specific antigen testing at a young age. Eur Urol 2011; Aug 10: (Epub ahead of print).
141. Ito K, Kubota Y, Yamamoto T, et al. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0ng/mL or less. Cancer 2001; 91: 744-51. (Pubitemid 32173299)
142. Roobol MJ, Grenabo A, Schröder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 2007; 99: 1296-303. (Pubitemid 47398681)
143. Aus G, Damber J, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level. Arch Intern Med 2005; 165: 1857-61.
144. American Urological Association. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Linthicum, MD: Americal Urological Association, 2009. http://www.auanet.org/content/media/psa09.pdf
145. McKenzie P, Delahunt B, deVoss K, Ross B, Tran H, Sikaris K. Prostate specific antigen testing for the diagnosis of prostate cancer. Pathology 2011; 43: 403.
146. Jepson RG, Hewison J, Thompson AGH, Weller D. How should we measure informed choice? The case of cancer screening. J Med Ethics 2005; 31: 192-6. (Pubitemid 40542127)
147. Scales CD, Antonelli J, Curtis LH, Schulman KA, Moul JW. Prostate-specific antigen screening among young men in the United States. Cancer 2008; 113: 1315-23.
148. Staples MP, Giles GG, English DR, et al. Risk of prostate cancer associated with family history in an era of rapid increase in prostate cancer diagnosis (Australia). Cancer Causes Control 2003; 14: 161-6. (Pubitemid 36539522)
149. Zeegers M, Jellema A, Ostrer H. Empiric risk of prostate cancer for relatives of patients with prostate cancer: A meta-analysis. Cancer 2003; 97: 1894-902.
150. Nadler RB. The case for prostate-specific antigen screening starting at age 40. Cancer 2008; 113: 1278-81.
151. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute. 2008 (cited November 2011). http://seer.cancer.gov/csr/1975-2005/
152. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445-52.
153. Smith P, Supramaniam R, Marshall VR, Armstrong BK. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aust 2008; 189: 315-8.
154. General Medical Council. Seeking Patients' Consent: The Ethical Considerations. London: General Medical Council, 1999.
155. Hedelin H, Claesson BE, Wilpart A. Febrile reactions after transrectal ultrasound-guided prostatic biopsy: a retrospective study. Scand J Urol Nephrol 2011; 45: 393-6.
156. Suzuki M, Kawakami S, Asano T, et al. Safety of transperineal 14-core systematic prostate biopsy in diabetic men. Int J Urol 2009; 16: 930-5.
157. Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, Young PR. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology 2005; 65: 735-9. (Pubitemid 40523009)
158. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. Clin Oncol 2004; 22: 2141-9. (Pubitemid 41095147)
159. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early stage prostate cancer: Review of the current literature. Cancer 2008; 112: 1650-9. (Pubitemid 351536825)
160. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31.
161. Wu JN, Dall'Era MA. Active surveillance for localized prostate cancer current practices and recommendations. ScientificWorldJournal 2010; 10: 2352-61.
162. Klotz L. Active surveillance for prostate cancer: patient selection and management. Curr Oncol 2010; 17: S11-7.
163. O'Neill O. Some limits of informed consent. J Med Ethics 2003; 29: 4-7. (Pubitemid 36231456)
164. Edwards A, Elwyn G. Understanding risk and lessons for clinical risk communication about treatment preferences. Qual Health Care 2001; 10: I9-13.
165. Stapleton H, Kirkham M, Thomas G. Qualitative study of evidence based leaflets in maternity care. BMJ 2002; 324: 639.
166. MacKenzie R, Chapman S, Holding S, McGeechan K. 'A matter of faith, not science': analysis of media coverage of prostate cancer screening in Australian news media 2003-2006. J R Soc Med 2007; 100: 513-21. (Pubitemid 350273404)
167. Sikaris KA. Observations on the impact of Sam Newman's prostate cancer publicity on pathology testing in men. Clin Biochem Rev 2008; 29: S50.
168. Towle A, Godolphin W, Greenhalgh T. Framework for teaching and learning informed shared decision making. BMJ 1999; 319: 766-71. (Pubitemid 29431536)
169. Elwyn G, Charles C. Shared decision making: the principals and the competences. In: Edwards A, Elwyn G, editors. Evidence Based Patient Choice: Inevitable or Impossible? Oxford: Oxford University Press, 2001; 119-43.
170. Schofield T. Evidence-based patient choice in primary health care. In: Edwards A, Elwyn G, editors. Evidence Based Patient Choice: Inevitable or Impossible? Oxford: Oxford University Press, 2001;181-90.
171. Robinson A, Thomson R. Variability in patient preferences for participating in medical decision making: implication for the use of decision support tools. Qual Health Care 2001; 10: I34-8.
172. The Cancer Council Australia, Australian Prostate Cancer Collaboration, The Urological Society of Australia and New Zealand, Andrology Australia, Prostate Cancer Foundation of Australia. The Early Detection of Prostate Cancer in General Practice: Supporting Patient Choice. 2007 (cited November 2011). http://www.andrologyaustralia.org/docs/PSAde cisioncard20041007.pdf
173. Stapleton AMF, Johns RL, Kopsaftis T, Tamblyn DJ. Abnormal PSA tests: Delays in referral. Aust Fam Physician 2008; 37: 84-8
174. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
175. Logothetis CJ, Schellhammer PF. High grade prostate cancer and the prostate cancer prevention trial. Cancer Prev Res 2008; 1: 151-2.
176. Freedland SJ, Andriole GL. Making an imperfect marker better. Eur Urology 2011; 59: 194-6.
177. Li XM, Li J, Tsuji I, Nakaya N, Nishino Y,Zhao XJ. Mass screening-based case-control study of diet and prostate cancer in Changchun, China. Asian J Androl 2008; 10: 551-60 (Pubitemid 351865761)